THALIDOMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H10N2O4
Molecular Weight	258.2295
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C1N(C2CCC(=O)NC2=O)C(=O)C3=CC=CC=C13

InChI

InChIKey=UEJJHQNACJXSKW-UHFFFAOYSA-N

InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB01041
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf

Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right-handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans. In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor. Thalidomide is used for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Thalidomide is sold under the brand name Immunoprin, among others.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Protein cereblon 10 Target ID: Q96SW2 Gene ID: 51185.0 Gene Symbol: CRBN Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8146
TNF-alpha 18 Target ID: CHEMBL1825 Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8146	200.0 µM [IC50]
Nuclear factor NF-kappa-B p105 subunit 4 Target ID: CHEMBL3251 Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8146
Fibroblast growth factor receptor 2 25 Target ID: CHEMBL4142 Sources: http://www.drugbank.ca/drugs/DB01041	Inhibitor 8146
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11909713	Inhibitor 8146

Conditions

Condition	Modality	Targets	Highest Phase	Product
Multiple myeloma 153 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf	Primary		Approved 8307	THALOMID Approved Use THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Launch Date 9.0046077E11
Erythema nodosum leprosum 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020785s051lbl.pdf	Primary		Approved 8307	THALOMID Approved Use THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Launch Date 9.0046077E11

C_max

Value	Dose	Co-administered	Analyte	Population
2 mg/L REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
19.8 mg × h/L REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.17 h REVIEW https://www.ncbi.nlm.nih.gov/pubmed/15080764	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:		THALIDOMIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
45% DRUG LABEL https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01041.pdf?1265922802			THALIDOMIDE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Co-administed with:: Carboplatin, i.v(1/21 days) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397	unhealthy, 11 n = 10 Health Status: unhealthy Condition: Cancer Age Group: 11 Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397	DLT: Somnolence... Dose limiting toxicities: Somnolence (20%) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397
400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Co-administed with:: Carboplatin, i.v(1/21 days) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397	unhealthy, 11 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 11 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397	DLT: Ataxia... Dose limiting toxicities: Ataxia (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397
150 mg 2 times / day multiple, oral MTD Dose: 150 mg, 2 times / day Route: oral Route: multiple Dose: 150 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658	unhealthy, 57 n = 7 Health Status: unhealthy Condition: Hepatocellular carcinoma Age Group: 57 Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658	Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658
200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658	unhealthy, 57 n = 2 Health Status: unhealthy Condition: Hepatocellular carcinoma Age Group: 57 Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658	DLT: Dyspnea... Dose limiting toxicities: Dyspnea (50%) Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658
400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Erythema nodosum leprosum Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1	Disc. AE: Fetal damage, Deep vein thrombosis... AEs leading to discontinuation/dose reduction: Fetal damage Deep vein thrombosis Pulmonary embolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Somnolence	20% DLT	400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Co-administed with:: Carboplatin, i.v(1/21 days) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397	unhealthy, 11 n = 10 Health Status: unhealthy Condition: Cancer Age Group: 11 Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397
Ataxia	16.7% DLT	400 mg/m2 1 times / day multiple, oral MTD Dose: 400 mg/m2, 1 times / day Route: oral Route: multiple Dose: 400 mg/m2, 1 times / day Co-administed with:: Carboplatin, i.v(1/21 days) Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397	unhealthy, 11 n = 6 Health Status: unhealthy Condition: Cancer Age Group: 11 Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15514381 Page: p.4397
Dyspnea	50% DLT	200 mg 2 times / day multiple, oral Studied dose Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658	unhealthy, 57 n = 2 Health Status: unhealthy Condition: Hepatocellular carcinoma Age Group: 57 Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/16520988 Page: p.658
Deep vein thrombosis	Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Erythema nodosum leprosum Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1
Fetal damage	Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Erythema nodosum leprosum Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1
Pulmonary embolism	Disc. AE	400 mg 1 times / day multiple, oral Recommended Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Erythema nodosum leprosum Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf Page: p.1

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY545063	https://www.001chemical.com/chem/2614-06-4
001 Chemical	NO12019	https://www.001chemical.com/chem/50-35-1
001 Chemical	DY573864	https://www.001chemical.com/chem/841-67-8
3B Scientific (Wuhan) Corp	3B1-00279	http://www.3bsc.com/index/pro_info.php?id=20491
3B Scientific (Wuhan) Corp	3B3-004810	http://www.3bsc.com/index/pro_info.php?id=26694
AA Blocks	AA006UKW	https://www.aablocks.com/goods/Goods/detail?id=AA006UKW
AEchem Scientific Corp., USA	AE1-013135	http://www.aechemsc.com/info_products/AE1-013135.php
AHH Chemical co.,ltd	MT-59367	http://www.ahhchemical.com/product/MT-59367.html
AK Scientific, Inc. (AKSCI)	570010	http://www.aksci.com/item_detail.php?cat=570010
AK Scientific, Inc. (AKSCI)	J90042	http://www.aksci.com/item_detail.php?cat=J90042
Aaron Chemicals	AR006VCO	http://www.aaronchem.com/50-35-1
AbMole Bioscience	M2225	http://www.abmole.com/products/thalidomide.html
Accela ChemBio Inc	SY052614	http://www.accelachem.com/cn/search.html?keyword=SY052614&attname=GoodsCode
Achemo Scientific Limited	AC-15639	http://www.achemo.com/search/?Keyword= 50-35-1
Achemtek	0104-022155	http://www.achemtek.com/50-35-1
Alfa Chemistry	AP50351-A	https://reagents.alfa-chemistry.com/product/thalidomide-cas-50-35-1-12112.html
Alfa Chemistry	AP50351-B	https://reagents.alfa-chemistry.com/product/thalidomide-cas-50-35-1-12113.html
Allbio Pharm Co., Ltd	AD04559	http://www.allbiopharm.com/product/n/AD04559
Alsachim	945	http://www.alsachim.com/product-C3127-glo.bal-view.html
Anward	ANW-53225	http://www.anward.com/pro_result/39676
Ark Pharm	AK-91024	http://www.arkpharminc.com/products/50-35-1.html
Aronis	ARONIS24496	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=1636
AstaTech, Inc.	35914	http://www.astatechinc.com/CPSResult.php?CRNO=36278
Aurum Pharmatech LLC	M-1523	http://www.Aurumpharmatech.com/Product/ProductDetails/M_1523
AvaChem Scientific	1620	http://www.avachem.com/productSearch.asp?1620
Axon MedChem	3324	https://www.axonmedchem.com/product/3324
BLD Pharm	BD153744	http://www.bldpharm.com/products/50-35-1.html
BOC Sciences	1219177-18-0	https://www.bocsci.com/thalidomide-d4-cas-1219177-18-0-item-255467.html
BioChemPartner	BCP19772	http://www.biochempartner.com/50-35-1-BCP19772
BioCrick	BCC2248	http://www.biocrick.com/Thalidomide-BCC2248.html
BioSynth	W-105969	https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-105969.html
Boerchem	BC204656	http://www.boerchem.com/?product_34445.html
BroadPharm	BP-30256	https://www.broadpharm.com/web/product.php?catalog=BP-30256
CSNpharm	CSN12073	https://www.csnpharm.com/products/thalidomide.html
Calbiochem	585970	http://www.emdbiosciences.com/product/585970
Chem Scene	CS-1084	http://www.chemscene.com/50-35-1.html
ChemMol	30102213	http://www.chemmol.com/chemmol/30102213.html
ChemMol	44001905	http://www.chemmol.com/chemmol/44001905.html
ChemMol	49409208	http://www.chemmol.com/chemmol/49409208.html
ChemMol	97900477	http://www.chemmol.com/chemmol/97900477.html
Chemenu	CM110594	http://www.chemenu.com/products/CM110594
Chemspace	CSSB00000747566	https://chem-space.com/CSSB00000747566
Clearsynth	CS-O-02490	https://www.clearsynth.com/en/CSO02490.html
Clearsynth	CS-T-61979	https://www.clearsynth.com/en/CST61979.html
Clearsynth	CS-T-61981	https://www.clearsynth.com/en/CST61981.html
DC Chemicals	DC9009	http://www.dcchemicals.com/product_show-Thalidomide.html
Debye Scientific	DB-051759	http://www.debyesci.com/cas_50-35-1.html
EMD Millipore	585970	http://www.emdbiosciences.com/product/585970
Finetech	FT-0675130	http://www.finetechnology-ind.com/prod/detail/pub/1219177-18-0.html
Finetech	FT-0600001	http://www.finetechnology-ind.com/prod/detail/pub/2614-06-4.html
Finetech	FT-0631211	http://www.finetechnology-ind.com/prod/detail/pub/50-35-1.html
Finetech	FT-0602275	http://www.finetechnology-ind.com/prod/detail/pub/841-67-8.html
Glentham Life Sciences	GP4232	http://www.glentham.com/products/product/GP4232/
Hairui	HR134772	http://www.hairuichem.com/en/product/50-35-1.html
LGC Standards	LGCFOR0940.00	https://www.lgcstandards.com/US/en/p/LGCFOR0940.00
LGC Standards	MM0940.00	https://www.lgcstandards.com/US/en/p/MM0940.00
Lab Network	LN00243537	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00243537
Lumtec	K0775	http://www.lumtec.com.tw/portal_c1_cnt_page.php?owner_num=c1_290785&button_num=c1&folder_id=32213&cnt_id=259223&search_field=&search_word=&search_field2=&search_word2=&search_field3=&search_word3=&bool1=&bool2=&search_type=1&up_page=2
MedChem Express	HY-14658	https://www.medchemexpress.com/thalidomide.html
Molcore	MC545063	https://www.molcore.com/product/2614-06-4
Molcore	CS12019	https://www.molcore.com/product/50-35-1
Molcore	MC573864	https://www.molcore.com/product/841-67-8
OChem	5340	http://www.ocheminc.com/index.php?act=psearch&pid=153T873
Renno Tech	RP29207	http://www.rennotech.com/product_show.asp?id=34816
Selleck Chemicals	S1193	http://www.selleckchem.com/products/Thalidomide.html
Sigma-Aldrich	T144_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/t144?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1652500_USP	https://www.sigmaaldrich.com/catalog/product/usp/1652500?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S548287	http://www.smolecule.com/products/s548287
Smolecule	S904079	https://www.smolecule.com/products/s904079
TCI (Tokyo Chemical Industry)	T2524	http://www.tcichemicals.com/eshop/en/us/commodity/T2524/index.html
THE BioTek	bt-287694	https://www.thebiotek.com/product/inhibitors/bt-287694
Tocris	652	https://www.tocris.com/products/thalidomide_0652
VladaChem	VL273087-500mg	https://www.vladachem.com/product.php?products=50-35-1
W&J PharmaChem	101000	http://www.wjpharmachem.com/new/101000.html
Yuhao Chemical	RT18984	http://www.chemyuhao.com/50-35-1.html
abcr GmbH	AB347541	http://www.abcr.com/shop/en/AB347541
eNovation Chemicals	D480514	http://www.enovationchem.com/productDetails.asp?productID=D480514
eNovation Chemicals	D402693	https://www.enovationchem.com/ProductDetails.asp?ProductID=D402693
iChemical	EBD17683	http://www.ichemical.com/products/50-35-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-6327754946	https://mcule.com/MCULE-6327754946/

PubMed

Title	Date	PubMed
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.	2001	11400948
Thalidomide in gastrointestinal disorders.	2001	11398909
Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-alpha production in vitro.	2001 Apr	11354662
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.	2001 Apr	11345648
Thalidomide use: past history and current implications for practice.	2001 Apr	11338756
The irreplaceable image. Thalidomide in refractory myeloma patients: early changes in bone marrow cellularity.	2001 Apr	11325662
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.	2001 Apr	11325648
Thalidomide treatment of resistant or relapsed multiple myeloma patients.	2001 Apr	11325647
Differential effects of thalidomide on angiogenesis and tumor growth in mice.	2001 Apr	11321364
Treatment of severe esophageal Crohn's disease with thalidomide.	2001 Apr	11316198
[Teratology, 40 years after the thalidomide tragedy].	2001 Feb	11387997
Pharmacotherapeutic options in inflammatory bowel disease: an update.	2001 Feb	11344586
Scleroderma.	2001 Feb	11328637
Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.	2001 Feb	11321389
Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B.	2001 Jan	11367517
Severe cutaneous ulceration following treatment with thalidomide for GVHD.	2001 Jan	11281398
[New concepts about atopic dermatitis].	2001 Jan-Feb	11398366
Clinical aspects and management of AIDS-related Kaposi's sarcoma.	2001 Jul	11423260
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.	2001 Jul 1	11418482
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.	2001 Jul 15	11435324
Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro.	2001 Jul-Aug	11399936
Thalidomide-induced amenorrhoea: two cases.	2001 Jun	11422077
[Thalidomide and cancer--revival of a drug].	2001 Jun	11420856
Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group.	2001 Jun	11411542
Disease controlling antirheumatic therapy in spondyloarthropathy.	2001 Jun	11409153
Thalidomide dose proportionality assessment following single doses to healthy subjects.	2001 Jun	11402635
Color Doppler ultrasonography of the superior mesenteric artery for prenatal ultrasonographic diagnosis of a left-sided congenital diaphragmatic hernia.	2001 Jun	11400943
Effectors of inflammation in actinic prurigo.	2001 Jun	11369907
Deep venous thrombosis and thalidomide therapy for multiple myeloma.	2001 Jun 21	11419443
Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.	2001 Jun 22	11297551
[Thalidomide and thrombosis: three observations].	2001 Jun 9	11433688
Thalidomide-induced sensory neuropathy.	2001 Mar	11345184
Targeting of vasculature in cancer and other angiogenic diseases.	2001 Mar	11334027
[The return of thalidomide].	2001 Mar	11320855
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.	2001 Mar	11317960
Cutaneous lupus erythematosus.	2001 Mar	11308132
Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma.	2001 Mar 10	11416969
Systemic lupus erythematosus.	2001 Mar 31	11293608
[Comparative treatment between thalidomide and transfer factor in severe atopic dermatitis].	2001 Mar-Apr	11421176
[Sarcoidosis: thalidomide treatment in ten patients].	2001 May	11427794
Enantioseparation of aminoglutethimide and thalidomide by high performance liquid chromatography or supercritical fluid chromatography on mono-2 and mono-6-O-pentenyl-beta-cyclodextrin-based chiral stationary phases.	2001 May	11391677
Is infliximab effective for induction of remission in patients with ulcerative colitis?	2001 May	11383596
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.	2001 May	11380408
Transcending conventional therapies: the role of biologic and other novel therapies.	2001 May	11380043
Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.	2001 May	11380040
Synthesis and immunological activity of water-soluble thalidomide prodrugs.	2001 May	11377186
Thalidomide and its dermatologic uses.	2001 May	11370795
Novel approaches to the treatment of chronic graft-versus-host disease.	2001 May	11322865
Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens.	2001 May	11302825
Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis.	2001 May-Jun	11407104

Patents

Sample Use Guides

In Vivo Use Guide

MM: 200 mg orally once daily. The recommended dose of dexamethasone is 40 mg/day on days 1-4, 9-12, and 17-20 every 28 days. • ENL: 100 to 300 mg/day for an episode of cutaneous ENL. Up to 400 mg/day for severe cutaneous ENL.

Route of Administration: Oral

In Vitro Use Guide

The minimum dose of thalidomide used (1 uM) inhibited TNF-α production in HTLV-1-infected subjects in vitro.

Name

Type

Language

THALIDOMIDE

Official Name

English

K-17

Code

English

KEVADON

Brand Name

English

THALIDOMIDE [JAN]

Common Name

English

THALIDOMIDE [HSDB]

Common Name

English

Thalidomide [WHO-DD]

Common Name

English

THALIDOMIDE [MART.]

Common Name

English

2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE

Systematic Name

English

CONTERGAN

Brand Name

English

THALIDOMIDE [VANDF]

Common Name

English

DISTAVAL

Brand Name

English

(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE

Systematic Name

English

PHARMION

Brand Name

English

THALIDOMIDE [USAN]

Common Name

English

N-PHTHALYLGLUTAMIC ACID IMIDE

Common Name

English

.ALPHA.-PHTHALIMIDOGLUTARIMIDE

Common Name

English

NSC-527179

Code

English

MYRIN

Brand Name

English

NSC-66847

Code

English

N-(2,6-Dioxo-3-piperidyl)phthalimide

Systematic Name

English

thalidomide [INN]

Common Name

English

THALIDOMIDE [USP MONOGRAPH]

Common Name

English

THALIDOMIDE [USP-RS]

Common Name

English

NEUROSEDYN

Brand Name

English

THALIDOMIDE [ORANGE BOOK]

Common Name

English

1H-ISOINDOLE-1,3(2H)-DIONE, 2-(2,6-DIOXO-3-PIPERIDINYL)-, (±)-

Systematic Name

English

CELGENE

Brand Name

English

THALOMID

Brand Name

English

2-(2,6-DIOXO-3-PIPERIDINYL)-1H-ISOINDOLE-1,3(2H)-DIONE

Systematic Name

English

SOFTENON

Brand Name

English

.ALPHA.-(N-PHTHALIMIDO)GLUTARIMIDE

Common Name

English

PANTOSEDIV

Brand Name

English

THALIDOMIDE [EMA EPAR]

Common Name

English

3-PHTHALIMIDOGLUTARIMIDE

Systematic Name

English

THALED

Brand Name

English

THALIDOMIDE [MI]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

43890